Sara Furia of Coeruleus Ltd. “Novel Solutions for Treatment of Daytime Sleepiness & ‘Hangover’ Effect” Video Interview at BioInvest Israel 2012

http://coeruleus.com/

Coeruleus Ltd., a research based company, is focused on the development of novel solutions for the treatment of a wide range of GABAA disorders, causing daytime sleepiness and “hangover” effect. Coeurleus therapeutic approach targets several unmet needs of insomnia patients and other GABAA related disorders (e.g., drug abuse and alcohol intoxication. SNNLive spoke to Sara Furia, VP of Regulatory Affairs at the BioInvest Israel Conference 2012 in Haifa.

Coeruleus is a pharmaceutical company, under Meytag Incubator, Katzrin, Israel. The company has founded at March 2009 and within 2 years of activities has achieved novel line of formulations, strong IP, performed pre-clinical and clinical phase I/IIA human study and approached the FDA for the 5052B fast track. Coeruleus therapeutic approach is based on a proprietary sublingual spray formulation incorporating the active ingredient Flumazenil, a generic drug indicated to counteract GABAA related sedatives, currently administered only via intravenous (IV) injection. The Company touches several UNMET NEEDS including the sleep market, drug abuse, alcohol intoxication and more. All are related to the GABAA. For more information about Coeruleus, check out their website. SNNLive welcomes Sara Furia, VP of Regulatory Affairs at Coeruleus Ltd.